r/Stocktradingalerts

I’m no trader, neither full stack developer, and I built AI stock market prediction engine using my expertise in WFM forecasting and planing phases. At the beginning it was just Idea to have quick accessible tool that does not require over sophisticated graphs with rulers and other tools to fit trend lines, but to just quickly give market direction and confidence level based on signal strength.

My early experience on stock market was in unregulated brokerage as a salesman. Seen guys admiring wolf of the wall street, boiler room and staff like that. And only thing I know for sure is that nobody can predict the market with absolute certainty and who does is either charlatan or scammer.

Anyways I built tool which makes sophisticated math behind the scenes and is free to everyone who wants to explore it.

At this stage I would like to have user side feedback, how easy it is to comprehend, what is confusing? what is uninviting etc.

QTREX Engineers Conductivity Itself to Address Quantum Computing's Cryogenic Heat-Load Barrier

The Company Filed a U.S. Provisional Patent Application Covering a Potentially Dominant Approach to the Critical Cryogenic Signal Pathway, Designed to Overcome Limitations of Traditional Manufacturing

July 01, 2026 08:40 ET | Source: QTREX Quantum Ltd.

Nes Ziona, Israel, July 01, 2026 (GLOBE NEWSWIRE) — QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced the development of a controlled-conductivity cryogenic microwave interconnect architecture designed to reduce heat conduction while preserving microwave signal performance in quantum computing systems. The Company filed a U.S. Provisional Patent Application with the United States Patent and Trademark Office ("USPTO") and the underlying technology is patent pending.

The Company's architecture is based on the intentional use of the Wiedemann–Franz Law, a fundamental law of physics linking electrical conductivity and electronic thermal conductivity in metallic conductors, with particular relevance at cryogenic temperatures. By applying this law at the materials-design level, The Company is turning conductivity into an engineering parameter for cryogenic quantum infrastructure, enabling conductive materials to be designed not only for signal transmission, but also for thermal behavior in ultra-low-temperature environments.

This capability is enabled by QTREX's control over the full materials-to-component process, from the chemistry and engineering of its manufacturing materials, through the additive manufacturing process, and into the final quantum-infrastructure component. This vertical control allows the Company to design material behavior for the specific requirements of quantum environments.

In superconducting quantum computing systems, microwave control and readout signals must travel from room-temperature electronics to quantum processors operating at millikelvin temperatures inside dilution refrigerators. Each interconnect line can also become a thermal pathway, conducting unwanted heat into the coldest stages of the system. This is already a significant constraint in today's cryogenic quantum systems and becomes increasingly critical as systems scale.

"Our ability to dictate material properties from the chemical formulation through to the final component gives us a unique competitive advantage in the quantum sector", said Dagi Ben-Noon, CEO of QTREX. "This architecture is a direct result of our vertically integrated approach, demonstrating how our advanced manufacturing capabilities has the potential of solving complex infrastructure challenges that traditional methods simply cannot address."

QTREX has seen strong interest from industry participants exposed to this development, reflecting the fact that this approach introduces a new way of thinking about cryogenic quantum infrastructure. This interest is already moving into near-term technical evaluation, with one of the Company's current industry collaborators expected to begin reviewing the architecture as early as next week.

About QTREX Quantum

QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

For more information, please visit: www.q-trex.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses Conductivity's ability to address quantum computing's cryogenic heat-load barrier; the Company's ability to enable conductive materials to be designed also for thermal behavior in ultra-low-temperature environments; the capabilities of the Company's controlled-conductivity cryogenic microwave interconnect architecture; approval of the Company's pending patents; the Company's ability to design material behavior for the specific requirements of quantum environments; the belief that constraints in today's cryogenic quantum systems become increasingly critical as systems scale; the belief that the Company has a unique competitive advantage in the quantum sector and how its advanced manufacturing capabilities has the potential of solving complex infrastructure challenges; any interest from industry participants; and the belief that the Company's approach may introduces a new way of thinking about cryogenic quantum infrastructure. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.

Company Contact

QTREX Quantum
Email: info@q-trex.com
Phone: +972-9-9664485

https://www.globenewswire.com/news-release/2026/07/01/3320608/0/en/QTREX-Engineers-Conductivity-Itself-to-Address-Quantum-Computing-s-Cryogenic-Heat-Load-Barrier.html

1. Zynquista (sotagliflozin) Type 1 Diabetes NDA Resubmission

Timing: Mid-2026 (company guidance)

This is probably the biggest near-term catalyst. • Lexicon expects to resubmit the NDA for Zynquista in Type 1 Diabetes based on FDA feedback and safety data from the STENO1 study. • Management has stated that a resubmission is anticipated in mid-2026, with the possibility of FDA approval later in 2026 if the required exposure and DKA safety data are achieved. 

Why it matters: A successful resubmission would reopen a large commercial opportunity that investors have largely discounted after prior regulatory setbacks.

⸻

2. SONATA-HCM Phase 3 Enrollment Completion

Timing: Mid-2026

Lexicon’s pivotal SONATA-HCM trial is evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM). • Enrollment of approximately 500 patients is expected to be completed by mid-2026. • The trial is running across roughly 130 sites in 20 countries. 

Why it matters: Completion of enrollment significantly de-risks execution and puts investors on a shorter timeline to the data readout.

⸻

3. SONATA-HCM Topline Data

Timing: Q1 2027

While slightly beyond the next six months, many investors will begin positioning for this event during 2026. • Lexicon continues to guide to Q1 2027 topline results. 

Why it matters: Positive data could create an entirely new indication for sotagliflozin and potentially transform the valuation of the company.

⸻

4. Pilavapadin (LX9211) Partnership Announcement

Timing: Potentially anytime in 2026

Pilavapadin is Lexicon’s non-opioid neuropathic pain candidate. • The FDA End-of-Phase 2 meeting was completed successfully. • Management has repeatedly stated that it is pursuing partnership discussions. 

Why it matters: A licensing deal could bring: • Upfront cash • Development funding • Validation of the program

Given Lexicon’s size, a partnership announcement could be a major stock-moving event.

⸻

5. Novo Nordisk LX9851 Milestones

Timing: Throughout 2026

LX9851 is an oral obesity asset licensed to Novo Nordisk. • Lexicon has already received milestone payments and says it may receive up to an additional $20 million of milestones during 2026.  • Novo initiated Phase 1 development in 2026. 

Why it matters: These are non-dilutive cash inflows and help fund operations without equity issuance.

⸻

6. International Sotagliflozin Approvals

Timing: Throughout 2026

Viatris is responsible for commercialization outside the U.S. and Europe. • Regulatory filings have been submitted in markets including Canada, Australia, and New Zealand. • Lexicon expects additional approvals and submissions during 2026. 

Why it matters: Each approval further validates the asset and may generate commercial or milestone revenue.